Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atopic dermatitis patients achieved freedom from itch on JAK inhibitor upadacitinib

Key clinical point: Treatment with the Janus kinase 1 selective inhibitor upadacitinib significantly improved itch versus placebo in patients with moderate to severe atopic dermatitis

Major finding: The placebo-adjusted difference in average pruritus Numerical Rating Scale scores was highest in the 30-mg daily group, at 37.7% by week 16 (P less than .001).

Study details: A post hoc analysis of a randomized, phase 2b study including 167 patients with moderate to severe atopic dermatitis.

Disclosures: Support for the study was provided by AbbVie. Dr. Reich reported disclosures related to AbbVie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo Pharma, Eli Lilly, Medac Pharma, Merck, Novartis, Pfizer, Regeneron, Takeda, UCB, and XenoPort.